Reaction tubes were incubated at 37 °C for 10 min and the reaction was stopped by adding 3 ml of a 0.1 M sodium pyrophosphate/10% trichloroacetic acid (TCA) cold solution. Radioactive polymerized filtrate collected on cellulose nitrate

transfer membranes (0.45 μm, Whatman) was dried and immersed in scintillating fluid. Radioactivity was measured in a scintillating counter and was expressed as counts per minute (CPM). Percentage inhibition was calculated as 100 − [(CPM with extract/CPM without extract) × 100]. Reactions were carried out in duplicate for each of two independent determinations. Azidothymidine (AZT) was used as a positive control.12 Binding of gp120 selleck chemical to CD4 was analysed using a commercially available gp120 Capture ELISA kit (GenxBio Health Science, India). To determine whether extracts could interfere with the binding of CD4 to gp120 by interaction with soluble gp120, each extract (Final conc. 10 mg/ml) was mixed with 25 ng of purified gp120 in a total volume of 100 μl and incubated

at room temperature for 1 h. This mixture was then added to microtiter plate wells coated with CD4 ligand and incubated at room temperature for 1 h. The solutions were aspirated and the wells were washed 3 times with washing buffer. The extent of gp120 binding was assessed by using detector reagent provided in the kit according to Tanespimycin manufacturer the manufacturer’s instructions. Negative control was set-up in parallel and heparin was included as a positive control.13 The present study, in-vitro antimicrobial activity of C. coromandelicum extract against 5 Gram-positive and Gram negative bacterial strains and 6 fungal strains

showed a broad spectrum of antimicrobial activity Table 1. The antimicrobial activities of plant extract are compared with standard antibiotics such as Ciprofloxacin and Amphotericin-B which were used as positive controls. The plant extract showed the zone of inhibition on Gram negative bacterial strains Escherichiae coli (19 mm), Klebsiella pneumoniae (14 mm), Salmonella typhi (22 mm), Shigella boydi (16 mm), Shigella Digestive enzyme flexneri (17 mm). The Gram positive strains Bacillus subtilis (14 mm), Micrococcus flavum (13 mm), Micrococcus leuteum (14 mm), Staphylococcus aureus (10 mm), Staphylococcus epidermis (10 mm) showed significant sensitivity. Among the both bacterial strain plant extract showed the very good sensitivity on Gram negative bacterial strain (S. typhi 22 mm) Fig. 1. The plant shows antifungal activity against Aspergillus niger (16 mm), Auricularia polytricha (17 mm), Arthrobotrys oligospora (13 mm), Candida albicans (18 mm), Chaetomella raphigera (15 mm), Monilinia fruticola (10 mm) Fig. 1. The agar well diffusion assay is a qualitative, non-standardized method useful only for the screening of large numbers of samples.

0003) was elicited by the MC.6M OMV vaccine ( Fig. 2B). However, the 2.0 μg dose of this vaccine induced significantly higher titres (p = 0.032) than the same dose of the FM OMV vaccine. A significant dose response in SBA (p = 0.004) was also found for the two doses of the FM OMV vaccine in a separate experiment (data not shown). The titres obtained with the 2.0 μg dose Ribociclib of both vaccines were significantly higher (p < 0.001) than those of the saline control group, whereas no significant differences

were observed between the saline controls and 0.5 μg of the MC.6M OMV vaccine ( Fig. 2B) or 0.5 μg of the FM OMV vaccine (data not shown). Specific antibody levels in immunized mice to the major OMPs were measured on immunoblots using the MC.6M OMV as antigen (data not shown). The 2.0 μg dose

of both vaccines induced similar Ig levels to Omp85, PorA, PorB, RmpM, OpcA, and OpaJ129 which were the main immunogenic bands on the blots. Significantly lower levels (p = 0.001–0.046) to these antigens were induced by 0.5 μg of the MC.6M vaccine. The FM OMV vaccine also gave significant dose responses (p ≤ 0.001) to the OMPs determined with FM OMVs as blotting antigen (data not shown). Antibodies to PorA contributed markedly to the bactericidal activity of the murine sera as there was a significant correlation between the Ig binding intensity to PorA on the blots and the bactericidal titres with both doses of each OMV vaccine (range of Pearson product moment correlation or Spearman rank order BGB324 in vivo correlation coefficients 0.580–0.856; p = 0.0004–0.048). The DIGE method was used to investigate differences in protein content between the OMV preparations prepared using different culture media. A total of 2005 spots were common amongst six gels from the three batches of OMVs from each medium.

The level of expression of about 97% of the protein spots did not change between the two OMV preparations (Table 1B). Only 3.2% (64 spots) exhibited a greater than 1.1-fold difference in the amount of protein (p = 0.00023–0.049). Forty-one proteins were more abundant in OMVs produced in MC.6M, whereas 23 were more abundant in OMVs produced in FM. Most of the spots that differed between the OMVs from the two media were in the basic region and included a range of molecular masses ( Fig. 3). High abundance spots, identified as the major whatever OMPs, i.e. PorA, PorB and OpcA, were excluded from accurate quantitative comparison due to their saturation in fluorescence intensity which exceeded the linear range of scanning conditions. Table 2 shows the details of 10 protein spots that were differentially expressed by meningococci grown in each of the media and in sufficient abundance to be identified by MS analysis. Lipoprotein NMB1126/NMB1164, hypothetical protein NMB2134 (2 spots), NspA, TonB-dependent receptor TdfH (2 spots), OMP NMB0088, MafA and OpcA (2 spots) were amongst the proteins that were more abundant in MC.6M OMVs.

From several independent Pifithrin-�� purchase measurements, means and standard deviations were calculated. Data are shown as mean ± SD from at least three separate

experiments. Testing for significant differences between means was carried out using one-way ANOVA and Dunnett’s Multiple Comparison test at a probability of error of 5% (*), 1% (**) and 0.1% (***). Two silica-based NPs were investigated: 1. Sicastar Red (amorphous silica; primary particles ca. 30 nm in diameter) and 2. AmOrSil [(poly(organosiloxane) with a shell of poly(ethylene oxide), PEO, to ensure particle solubility in water; primary particles ca. 60 nm in diameter)]. Fig. 1A depicts the viability (MTS assay) and membrane integrity (LDH assay) of the lung epithelial cell line H441 and the microvascular endothelial

cell line ISO-HAS-1 cultured in conventional monocultures (MC) after exposure to Sicastar Red and AmOrSil for 4 h in serum-free medium. According to MTS, H441 showed a significantly reduced viability at high concentrations of Sicastar Red (100 μg/ml: 14 ± 12%; 300 μg/ml: 60 ± 12% compared to untreated control uc), whereas AmOrSil did not have any effect (e.g. 300 μg/ml: 109 ± 12% compared to uc). Similar observations have been made for the microvascular endothelial cell line ISO-HAS-1 with Sicastar Red (300 μg/ml: 36 ± 18% and 100 μg/ml: 34 ± 4% of uc) as well as AmOrSil (300 μg/ml 111 ± 15% of uc). Sicastar Red did not cause a significant decrease in the mitochondrial activity at 60 μg/ml for both cell types (H441: 98 ± 15%

and ISO-HAS-1: 99 ± 12% of uc). With respect to buy Icotinib viability, similar effects were obtained for the membrane integrity after NP exposure. H441 showed a significant release of LDH after 4 h exposure to Sicastar Rutecarpine Red (300 μg/ml: 90 ± 7.5%, 100 μg/ml: 70 ± 13.6%, 60 μg/ml: 46 ± 22% of lysis control lc), whereas 6 μg/ml Sicastar Red did not show any toxic effects (14.2 ± 12% of lc). Similar to H441, ISO-HAS-1 also displayed a high LDH release at high concentrations (300 μg/ml: 77 ± 7.5%, 100 μg/ml: 57 ± 18% of lc) but not at 60 μg/ml (12 ± 5% of lc). AmOrSil did not cause a change in membrane integrity even at high concentrations of 300 μg/ml in H441 or ISO-HAS-1 (H441: 13 ± 11% and ISO-HAS-1: 4 ± 2.8% of lc). According to Fig. 1B, LDH release into the apical compartment (H441) of the coculture (CC) was firstly detected at a concentration of 100 μg/ml Sicastar Red (30 ± 5.6% of lysis control, 2-fold of untreated control uc), but to a lower extent as observed for the H441 in MC (57 ± 18% of lc). The LDH release of the H441 in CC further increased with increasing concentrations (300 μg/ml: 49.3 ± 12.4% of lc), which is also lower compared to the MC (90 ± 7.5% of lc). A concentration of 60 μg did not yield higher LDH levels (10.4 ± 2.5% of lc) on the contrary to the MC (46 ± 22% of lc).

41 × 109 bp. It is also assumed that there is only one oncogene of size 1925 contained in the canine genome. The safety factor is calculated to be 2.3 × 1011. This indicates that 230 billion doses of vaccine would need to be administered before an oncogene dosage PLX 4720 equivalent to 9.4 μg would be reached. Safety factor for infectivity due to a single provirus is similarly calculated, substituting the following values for those in Eq. (19): Qm = 2.5 μg; E[U] < 1 ng; Med0 = 450 bp; diploid size of host genome N = 4.82 × 109 bp; J0 = 1; n1 = 7000 bp. The safety factor for a single provirus is calculated to be 8.3 × 1013

or the equivalent of 83 trillion doses to induce an infective event. We repeat the calculations of safety factors for the example given in Section 4, using Eq. (1), which is a method suggested in Refs. [7] and [8]. The safety factors of oncogenicity and infectivity are determined to be 1.2 × 1010 www.selleckchem.com/products/Trichostatin-A.html and 1.7 × 109, respectively. These calculations overestimate risk due to oncogenicity by more than 19-fold. The overestimation issue for risk of infectivity is even more pronounced; the risk is overstated by more than 48,000 times. The overestimation stems from the fact that enzyme inactivation is not taken into

account. The method we propose in the paper clearly results in more accurate estimates of risks because of the inclusion of enzyme inactivation in its calculations. It is also worth noting that in all the calculations of safety to factors, we assume that the residual hcDNA is less than 1 ng. However, the intranasal administration of the vaccine is likely to reduce the residual hcDNA found in tissues which, if shown to be true, would further lower associated risks. Model validation is an integral part of a probabilistic method development. It ensures that a method is fit

for its intended use. The accuracy and reliability of the risk assessment approach we develop ideally should be validated by comparing its estimated values with observed events. However, before a biological product is approved for marketing and distributing, there are only a limited number of doses administered in human subjects during clinical development. Because the risks of oncogenicity and infectivity due to hcDNA are in general low, it would take many doses to observe some events. As a result, validation of the model based on empirical data can only be accomplished if one were to follow millions of doses for extended periods of time. This is one of the limitations the proposed method has. It is also worth pointing out that the quantity in Eq. (18) or (19) represents a point estimate of the safety factor. Because the parameters involved in the calculations are determined through analytical methods which have inherent variability, the accuracy and precision of the safety factor estimate are influenced by that of the analytical methods. It is advisable to conduct a sensitivity analysis of the safety factors.

He has been treated in the past for enlarged cysts with a percutaneous drainage of 1.2 L fluid in May 2007, followed by a seminal vesicle cyst laparoscopic decortication in December 2009. He had been stable and followed with Ibrutinib concentration computed tomographic (CT) scans of the pelvis over time. On presentation to the emergency department, his initial evaluation was significant only for discomfort associated with sharp 8/10 lower abdominal and perineal pain. Vital signs were stable and within normal limits, his physical examination was benign and urinalysis, complete blood count, and basic metabolic panel were all within normal limits. This prompted a CT scan of

his pelvis with intravenous contrast, which revealed a recurrent left seminal vesicle cyst as well as the development of a new large extraperitoneal fluid collection measuring 11.6 cm × 5.0 cm, suspicious for a hematoma. This can be visualized in Figure 1,

with an arrow depicting contrast extravasation suggestive of active hemorrhage from a cystic vessel. Despite normal stable vital signs, adequate pain control, and normal laboratory work, he was admitted for observation with serial laboratory draws. By hospital day 2, he was still doing well but his hemoglobin and hematocrit levels decreased steadily. With CT evidence of active bleeding in the setting of persistently decreasing blood counts, interventional radiology department was consulted for definitive management of his hemorrhagic PI3K assay seminal vesicle cyst. The interventional radiologist performed a percutaneous embolization through a left internal iliac angiogram using Gelfoam slurry and 500-700 μm Embospheres. Digital subtraction angiography was performed, which demonstrated ectatic vessels outlining the enlarged left seminal vesicle as demonstrated in Figure 2A. The inferior seminal vesicle artery followed by the left seminal vesicle artery were

isolated with subsequent placement of Gelfoam and Embospheres. Nonvisualization of contributory vessels to the see more left seminal vesicle was appreciated after Gelfoam embolization and can be seen in Figure 2B, suggesting successful embolization. The patient was kept overnight for observation and reassessment of complete blood counts. By postoperative day 1, he was asymptomatic with increasing hemoglobin and hematocrit values and was discharged in good condition with routine follow-up. The patient at 1-week follow-up described difficulty voiding and defecating, which was attributed to mass effect on the colon and bladder from the hematoma. Despite these symptoms, the patient’s blood counts remained stable. The patient remained stable hematologically without further hemorrhagic events. The patient had follow-up CT scans 1 year and 2 years after the procedure that demonstrated regression in size. In conclusion, seminal vesicle cysts are a very rare phenomenon, and clinically significant hemorrhagic seminal vesicle cysts are even less common.

The data show that adaptive immunity is not required for DI virus to protect SCID mice from acute influenza. However, in contrast to immune-competent animals, a delayed onset disease occurred about 1 week later, indicating that adaptive immunity is required to act in concert with DI virus to clear the infection. The 244 DI RNA used

here to protect mice was originally generated spontaneously during transfection of 293T cells with plasmids [32] to make infectious influenza A/PR/8/34 [18]. After 24 h, the 293T cells were trypsinized, mixed with MDCK cells and re-plated, and culture supernatants harvested 7 days later. Resulting virus was passaged twice in embryonated chicken’s eggs. The resulting mixture of 244 DI virus, packaged in a A/PR8 particle, and infectious helper A/PR8 virus was purified by differential centrifugation through sucrose. Stocks were resuspended in PBS containing 0.1% (w/v) bovine ATM Kinase Inhibitor serum albumin, standardized by haemagglutination titration, and stored in liquid nitrogen. Before inoculation into mice, helper virus infectivity was eliminated with a short burst (40 s) of UV irradiation at 253.7 nm (0.64 mW/cm2). This is referred to as ‘active DI virus’. The UV inactivation target is viral RNA, and UV

has little effect on the DI RNA because of its small target size, 395 nt compared with 13,600 nt for infectious virus. Longer UV irradiation (8 min) inactivated mouse-protecting activity ABT-263 clinical trial and provided a preparation that controlled for any immune system-stimulating or receptor-blocking effects (‘inactivated DI virus’). However, UV treatment did not completely destroy all DI RNA. UV did not affect haemagglutinin or neuraminidase activities. We used wild type C3H/He-mg (H-2k) mice (bred in-house), wild type Balb/c (H-2d)

mice (Harlan UK Ltd.), and mutant Balb/cJHan™Hsd-Prkdcscid mice (Harlan) with a defect in the Prkdc gene which encodes DNA-PK. This leads to aberrant VDJ recombination and hence deficient B and T cells. SCID mice have a normal complement of NK cells. Wild-type Balb/c mice required see more 2 × 103 ffu of WSN challenge virus to cause consistent but non-lethal clinical disease; this was twice the dose needed for C3H/He-mg mice [18]. Balb/cscid mice were also infected with 2 × 103 ffu of WSN. Adult mice (4–6 weeks old) were inoculated intranasally under light ether anaesthesia as previously described [33] and [34], with a 40-μl inoculum divided between the two nares. Mice were given various combinations of active DI virus, UV-inactivated DI virus, infectious challenge virus (A/WSN), or diluent. Infectious challenge viruses were titrated in mice to determine a dose for each that caused comparable respiratory disease. The health of mice was assessed clinically and by change in group weight [33].

They estimated that a child who did not experience any diarrhea would grow 0.42 cm more per year than a child with an average prevalence of diarrhea [7]. Roy found that children Ribociclib research buy who had experienced an episode of diarrhea in the previous year were significantly more likely to be categorized as malnourished using mid-upper arm circumference (MUAC) as the anthropometric indicator [15]. Qadri et al. found that children who had experienced an episode of acute gastroenteritis (AGE) caused by enterotoxigenic Escherichia coli (ETEC) were more likely to be malnourished or growth

stunted at two years of age compared to children who had not had ETEC diarrhea [16]. Another study by Black et al. found that ETEC diarrhea impacted weight gain, while Shigella diarrhea impacted Selleck Palbociclib growth in length or height [7]. Rotavirus vaccines are now recommended by the WHO for use in all national immunization programs, and introduction of the vaccines is strongly recommended in countries where deaths from diarrheal diseases account for greater than 10% of all under-five deaths [17] and [18]. The pentavalent rotavirus vaccine (PRV), RotaTeq™, was developed by Merck, and is a human–bovine reassortant vaccine

that is administered as a live-attenuated oral vaccine [19]. PRV was tested in a Phase 3 clinical trial called the Rotavirus Efficacy and Safety Trial (REST) that enrolled almost 70,000 children in high- or middle-income countries in the US, Finland, and nine other countries [19]. A complete three-dose series of PRV was found to have efficacy of 74% against rotavirus gastroenteritis of any severity, and 98% efficacy against severe disease caused by serotypes G1–G4 [19]. PRV has subsequently been found to have lower efficacy in developing country settings, with efficacy in Asia observed at about 48% and in Bangladesh at about

43% against severe rotavirus gastroenteritis (defined as Vesikari score ≥11) [20], [21] and [22]. Because rotavirus vaccines are intended to prevent Rutecarpine episodes of severe rotavirus gastroenteritis, and these episodes may result in growth retardation, we hypothesized that vaccination with PRV would reduce malnutrition rates at varying time points during the vaccination series and up to three years of age as compared to vaccination with placebo. To the best of our knowledge, there is no published research documenting the impact of rotavirus vaccination on malnutrition. In order to address this important research gap, this study sought to examine the impact of vaccination with PRV on indicators of malnutrition among a cohort of children enrolled in a vaccine trial. A PRV study entitled Efficacy, Safety, and Immunogenicity of RotaTeq™ Among Infants in Asia and Africa was conducted at the Matlab field site of the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B) in collaboration with PATH and Merck Research Laboratories, and has been previously described [21].

During the six months after admission to the study, 72% of non-ambulatory people after stroke who received treadmill walking with body weight support achieved independent walking compared with 60% of the control group who received assisted overground walking (Ada et al 2010). It has been found that treadmill walking is biomechanically different to overground walking (Van Ingen Schenau 1980). Less well known is whether these differences are important in training walking after stroke. Hesse (2008) reported that some clinicians were reluctant to use treadmill walking

TSA HDAC as an intervention after stroke for fear patients would practise abnormal walking patterns. Others have noted that treadmill walking may not be comparable to overground walking (Collett et al 2007). Treadmill walking with body weight support not only needs to be shown to be effective, but it also needs to be shown not to be deleterious selleck compound in terms of the quality of walking. This would then remove potential barriers to widespread implementation of the intervention in stroke rehabilitation. The MOBILISE trial therefore included secondary outcome measures, such as walking speed and stride length, that reflected walking quality. Treadmill walking may also have potential benefits from the extra practice that treadmill walking with body weight support affords.

For example, capacity in the form of being able to walk further may be enhanced as a result of the additional practice. Furthermore, confidence to walk and participate in the community may be enhanced. Therefore, other secondary outcome measures included were walking capacity, perception of walking ability, community participation and falls. The purpose of this paper is to report the analysis of the secondary outcomes from the MOBILISE trial. Therefore, the specific research questions were: 1. Is treadmill walking with body weight support during inpatient rehabilitation detrimental to walking quality compared with Carnitine dehydrogenase assisted overground walking? Answering these questions should facilitate the translation of evidence into practice. An analysis of secondary

outcomes of the MOBILISE trial was performed. The MOBILISE trial was a prospective, multicentre, randomised trial comparing treadmill walking with body weight support versus assisted overground walking in non-ambulatory people after stroke. Non-ambulatory stroke patients were screened by an independent recruiter and randomly allocated into either an experimental group or a control group. Randomisation was stratified by centre and severity using randomly permuted blocks of four or six patients. Sitting balance (Item 3) of the Motor Assessment Scale for Stroke was used to stratify severity. Those with scores 0–3 were randomised separately to those with scores 4–6. The allocation sequence was computer-generated before commencement of the study and centrally located.

1). Similar dilation has also been associated with anoxia in placental samples that are not fixed immediately after

delivery, or are malperfused in vitro [27]. We have recently provided the first molecular evidence of activation of the UPR in placentas from cases of normotensive intrauterine growth retardation (IUGR) and from IUGR associated with early-onset pre-eclampsia (IUGR+PE) [25]. In both sets of placentas we observed phosphorylation of eIF2α, which was absent in control placentas delivered at term by caesarean section. The degree of phosphorylation was greater in the IUGR+PE cases, suggesting a higher level of ER stimulation. Commensurate with this hypothesis, we observed

Bioactive Compound Library solubility dmso increased levels of CHOP in the IUGR+PE cases, but not in IUGR alone, and immunohistochemistry localised this principally to the syncytiotrophoblast and the endothelial cells of the fetal capillaries. There was also Pfizer Licensed Compound Library purchase a rise in GRP94 in IUGR+PE, but not in IUGR alone. No change in GRP78 was observed in either pathology, and interestingly was also not found under oxygen-glucose deprivation in JEG-3 cells where there was an increase of P-eIF2α and CHOP and cleavage of Xbp-1 mRNA [28]. Extensive splicing of Xbp1 mRNA was seen in both IUGR and IUGR+PE placentas, and was not significantly different between the two conditions. Given both the morphological and molecular evidence of ER stress in early-onset pre-eclamptic placentas, what might the significance be

for the pathogenesis of the disorder? ER stress can be induced by many stimuli, and the precise cause in pre-eclampsia is not known. However, an ischaemia–reperfusion-type injury is a strong possibility given the associated spiral arterial pathology. Early-onset pre-eclampsia, along with IUGR, has long been associated with deficient conversion of the endometrial spiral arteries secondary to poor trophoblast invasion. Conversion normally extends from the placental interface as far as the inner third of the myometrium, and is associated with the Ribonucleotide reductase loss of smooth muscle and the elastic lamina from the vessel walls. Exact quantification of the degree of conversion is difficult, given the small size and number of the samples available for study. However, there is general agreement between studies that the myometrial segments of the arteries are more adversely affected in pathological pregnancies than the decidual segments, and that the deficit is greater in cases associated with pre-eclampsia than IUGR alone [29], [30], [31], [32] and [33]. The portion of the artery just below the endometrial/myometrial boundary represents a specialised highly contractile segment [34], that is thought to prevent excessive blood loss at the time of menstruation.

Brazil’s national immunization program provides vaccines included in the recommended immunization schedule through the Unified Health System [Sistema Unico de Saúde (SUS)], Brazil’s public health system. State governments have autonomy to purchase and provide vaccines not included in the national immunization program through the state immunization program. Bahia, with a population of 13.6 million inhabitants, ranks fourth most populous among Brazil’s 27 PFI-2 states (including the Federal District) and had an annual

estimated health budget of US$ 1.5 billion in 2010 [6]. In February 2010, MenC-tetanus toxoid conjugate vaccine (MenC-TT, Neisvac-C®, Baxter Vaccines) was introduced into the routine infant immunization schedule in the state of Bahia, Brazil, with financing from the state government. After August, 2010, infants began receiving MenC-CRM197 Everolimus conjugate vaccine (Novartis Vaccines), which was provided to all states for universal infant immunization through Brazil’s national immunization program. The recommended schedule in all state immunization programs was two doses in the first year of life (either at 2 and 4 months or 3 and 5 months of age), followed by one dose in the second year of life (at 12 or 15 months). Catch-up vaccination was provided for children younger

than two years ADAMTS5 of age in most states. In the state of Bahia, catch-up vaccination included children younger

than five years; one dose of MenC was recommended for those at least 12 months of age in February 2010. In addition, the state of Bahia purchased 1,876,863 doses of MenC-TT in 2010 to control the epidemic of meningococcal serogroup C disease in Salvador, the state capital and most populous city (estimated population 2,676,606, 21% of the state population). MenC-TT vaccine was used for mass vaccination of persons 10–19 years old in May and June 2010. In August 2010, the state government received 447,983 doses of MenC-CRM197 from Brazil’s national immunization program, which were used for mass vaccination of persons 20–24 years with a single dose. Children 5–9 years of age were not vaccinated. MenC vaccination was offered at 52 vaccination posts throughout the city. Vaccination was offered on Saturday and Sunday at the beginning of each phase to minimize disruption of normal vaccination services. Social mobilization focused on the first two days of vaccination for each age group. Due to poor turnout among 20–24 year olds in 2010, vaccination was offered for persons in this age group during the second weekend in February 2011, and at large universities the following week. MenC doses administered by age group at each vaccination post were reported to the immunization unit of the Salvador municipal health department.